Cargando…

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study

The European LeukaemiaNet (ELN) measurable residual disease (MRD) working group has published consensus guidelines to standardize molecular genetic MRD testing of the t(8;21)(q22;q22.1) RUNX1::RUNX1T1, inv(16)(p13.1q22) CBFB::MYH11, t(15;17)(q24.1;q21.2) PML::RARA, and NPM1 type A markers. A study f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scott, Stuart, Dillon, Richard, Thiede, Christian, Sadiq, Sadia, Cartwright, Ashley, Clouston, Hazel J., Travis, Debbie, Mokretar, Katya, Potter, Nicola, Chantry, Andrew, Whitby, Liam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368676/ https://www.ncbi.nlm.nih.gov/pubmed/36939402 http://dx.doi.org/10.1182/bloodadvances.2022009379

Ejemplares similares

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study
por: Vasseur, Loïc, et al.
Publicado: (2023)

Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
por: Stasik, Sebastian, et al.
Publicado: (2022)

Coping strategies in patients with acute myeloid leukemia
por: Amonoo, Hermioni L., et al.
Publicado: (2022)

In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice
por: Li, Bin E., et al.
Publicado: (2023)

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
por: Kramer, Michael H., et al.
Publicado: (2022)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Vitamin C and D supplementation in acute myeloid leukemia
por: Mouchel, Pierre Luc, et al.
Publicado: (2023)

A global study for acute myeloid leukemia with RARG rearrangement
por: Zhu, Hong-Hu, et al.
Publicado: (2023)

Telomeric repeat-containing RNA is dysregulated in acute myeloid leukemia
por: Catto, Luiz Fernando B., et al.
Publicado: (2023)

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
por: Lewis, Alexander C., et al.
Publicado: (2022)

Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia
por: Yamato, Genki, et al.
Publicado: (2022)

Optical genome mapping in acute myeloid leukemia: a multicenter evaluation
por: Levy, Brynn, et al.
Publicado: (2022)

Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting
por: Attardi, Enrico, et al.
Publicado: (2023)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
por: Wakita, Satoshi, et al.
Publicado: (2022)

Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression
por: Stratmann, Svea, et al.
Publicado: (2022)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia
por: Kirkey, Danielle C., et al.
Publicado: (2022)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
por: McCarter, Joseph G. W., et al.
Publicado: (2023)

BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes
por: Sunami, Yoshitaka, et al.
Publicado: (2022)

Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia
por: Conneely, Shannon E., et al.
Publicado: (2021)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia
por: Kumar, Rahul, et al.
Publicado: (2022)

Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity
por: Molteni, Elisabetta, et al.
Publicado: (2023)

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
por: Tahir, Stephen K., et al.
Publicado: (2023)

Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions
por: DeZern, Amy E., et al.
Publicado: (2023)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
por: Zhao, Lianzhong, et al.
Publicado: (2021)

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome
por: Iijima, Mayuko, et al.
Publicado: (2022)

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
por: Oñate, Guadalupe, et al.
Publicado: (2022)

In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies
por: Mercier, Francois E., et al.
Publicado: (2022)

TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice
por: Xie, Xiaoling, et al.
Publicado: (2023)

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
por: Moujalled, Donia M., et al.
Publicado: (2023)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms
por: Chovanec, Jack, et al.
Publicado: (2022)

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021)

Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
por: Rodriguez-Zabala, Maria, et al.
Publicado: (2023)

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
por: Nannya, Yasuhito, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c0lji7gdv1r4sgvcfrn08cu3md